Perspective Therapeutics Inc Financials
This page shows Perspective Therapeutics Inc (CATX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Perspective Therapeutics is operating as a cash-intensive development company, with capital raises funding research and asset buildout rather than revenue-driven operations.
The FY2024 financing surge of$289.4M arrived alongside$218.9M of investing outflow, a pairing that usually means the company was building capability, not just stockpiling cash. By FY2025, cash had fallen to$30.6M , which shows that last year's raise was already being turned into research capacity and long-lived assets rather than preserved as a large liquidity buffer.
FY2025 operating cash flow was
Liquidity is still meaningful, with a current ratio of 5.2x and only
Financial Health Signals
Perspective Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Perspective Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Perspective Therapeutics Inc reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Perspective Therapeutics Inc's EBITDA was -$110.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 24.5% from the prior year.
Perspective Therapeutics Inc reported -$103.1M in net income in fiscal year 2025. This represents a decrease of 30.1% from the prior year.
Perspective Therapeutics Inc earned -$1.40 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 13.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Perspective Therapeutics Inc recorded an outflow of $95.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 31.0% from the prior year.
Perspective Therapeutics Inc held $30.6M in cash against $1.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Perspective Therapeutics Inc's ROE was -49.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 22.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Perspective Therapeutics Inc invested $84.2M in research and development in fiscal year 2025. This represents an increase of 102.3% from the prior year.
Perspective Therapeutics Inc invested $12.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 76.6% from the prior year.
Not reported for fiscal year 2025.
CATX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.4M-76.8% | $6.2M-38.5% | $10.1M+3.9% | $9.7M+32.3% | $7.3M+23.5% | $5.9M+24.4% | $4.8M-0.2% | $4.8M+3.5% | $4.6M+9.2% | $4.2M-6.8% | $4.5M-10.8% | $5.1M-3.2% | $5.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $6.2M+25.3% | $4.9M+8.3% | $4.6M+6.8% | $4.3M+4.6% | $4.1M+4.0% | $3.9M-15.5% | $4.6M+4.5% | $4.4M+0.5% | $4.4M+0.9% | $4.4M+0.2% | $4.4M+7.0% | $4.1M |
| Gross Profit | N/A | N/A | N/A | $1.4M | $0-100.0% | $5.1M-0.1% | $5.1M+68.2% | $3.0M+65.4% | $1.8M+119.8% | $838K+549.6% | $129K-22.8% | $167K+185.0% | -$196K-230.8% | $150K-78.6% | $703K-39.2% | $1.2M |
| R&D Expenses | N/A | $84.2M+102.3% | $41.6M+95.4% | $21.3M+2319.0% | $881K-38.3% | $1.4M+26.7% | $1.1M-23.6% | $1.5M-15.6% | $1.7M+80.9% | $965K+82.8% | $528K-14.1% | $615K-8.0% | $669K+6.6% | $627K-19.7% | $781K-20.4% | $981K |
| SG&A Expenses | N/A | $30.2M+13.6% | $26.6M+26.3% | $21.1M+181.4% | $7.5M+59.6% | $4.7M+2.6% | $4.6M+9.6% | $4.2M+0.2% | $4.2M+6.3% | $3.9M+3.5% | $3.8M+57.7% | $2.4M-3.5% | $2.5M+8.5% | $2.3M-2.6% | $2.4M-2.8% | $2.4M |
| Operating Income | N/A | -$113.6M-25.0% | -$90.9M-122.0% | -$40.9M-372.1% | -$8.7M-151.7% | -$3.4M+0.9% | -$3.5M+33.8% | -$5.3M+21.9% | -$6.7M-6.7% | -$6.3M-24.1% | -$5.1M-17.2% | -$4.3M+5.5% | -$4.6M-12.8% | -$4.1M-13.0% | -$3.6M-21.4% | -$3.0M |
| Interest Expense | N/A | N/A | N/A | $84K | $0 | N/A | N/A | N/A | N/A | $0-100.0% | $1K-50.0% | $2K+126.5% | $883+12514.3% | $7-100.0% | $62K-71.5% | $217K |
| Income Tax | N/A | -$793K+62.2% | -$2.1M+20.9% | -$2.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| Net Income | N/A | -$103.1M-30.1% | -$79.3M-70.5% | -$46.5M-332.2% | -$10.8M-217.7% | -$3.4M+1.7% | -$3.4M+33.0% | -$5.1M+23.2% | -$6.7M-8.7% | -$6.2M-30.8% | -$4.7M-28.0% | -$3.7M+38.2% | -$6.0M-54.5% | -$3.9M-10.5% | -$3.5M-22.8% | -$2.8M |
| EPS (Diluted) | — | -$1.40-13.8% | -$1.23 | -$1.74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CATX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $267.0M-21.7% | $341.1M+248.4% | $97.9M+68.5% | $58.1M-17.5% | $70.4M+709.5% | $8.7M-7.7% | $9.4M+26.4% | $7.5M-39.2% | $12.3M-32.2% | $18.1M-21.3% | $23.0M-13.4% | $26.5M+276.3% | $7.1M-6.0% | $7.5M-4.9% | $7.9M |
| Current Assets | $148.4M-35.8% | $231.2M+1272.9% | $16.8M-68.4% | $53.2M-20.9% | $67.3M+1122.1% | $5.5M-24.7% | $7.3M+34.3% | $5.4M-47.1% | $10.3M-24.5% | $13.6M-16.5% | $16.3M-15.0% | $19.2M+332.4% | $4.4M+7.4% | $4.1M-2.0% | $4.2M |
| Cash & Equivalents | $30.6M-50.3% | $61.6M+566.6% | $9.2M-56.0% | $21.0M-67.1% | $63.8M+2568.4% | $2.4M-55.1% | $5.3M+104.8% | $2.6M-56.2% | $5.9M-41.5% | $10.1M+94.0% | $5.2M-31.9% | $7.7M+164.8% | $2.9M+8.5% | $2.7M+26.5% | $2.1M |
| Inventory | N/A | N/A | N/A | $1.4M+43.8% | $980K+51.9% | $645K+21.7% | $530K+7.3% | $494K+52.9% | $323K-3.3% | $334K-17.3% | $404K+12.3% | $360K-11.3% | $406K-8.7% | $444K-40.7% | $750K |
| Accounts Receivable | $6K-94.8% | $116K-90.0% | $1.2M-14.5% | $1.4M-32.3% | $2.0M | N/A | N/A | N/A | N/A | N/A | $1.0M+14.9% | $913K-1.2% | $924K+6.8% | $865K+9.1% | $793K |
| Goodwill | N/A | $0-100.0% | $24.1M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $59.9M+18.9% | $50.4M+122.1% | $22.7M+558.5% | $3.4M+14.6% | $3.0M+1.1% | $3.0M+70.8% | $1.7M-28.2% | $2.4M+45.5% | $1.7M-2.0% | $1.7M-23.4% | $2.2M-14.4% | $2.6M+53.5% | $1.7M+0.1% | $1.7M+17.5% | $1.4M |
| Current Liabilities | $28.7M+57.3% | $18.2M+16.4% | $15.7M+402.4% | $3.1M+73.1% | $1.8M+14.3% | $1.6M+40.5% | $1.1M-38.9% | $1.8M+65.9% | $1.1M+1.1% | $1.1M+0.2% | $1.1M-5.3% | $1.2M+45.5% | $793K+22.2% | $649K-16.2% | $774K |
| Long-Term Debt | $1.6M-3.1% | $1.7M-2.8% | $1.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $207.0M-28.8% | $290.7M+286.6% | $75.2M+37.6% | $54.6M-18.9% | $67.4M+1077.8% | $5.7M-25.5% | $7.7M+52.7% | $5.0M-52.6% | $10.6M-35.4% | $16.4M-21.1% | $20.8M-13.2% | $24.0M+346.4% | $5.4M-7.8% | $5.8M-9.8% | $6.5M |
| Retained Earnings | -$334.8M-44.5% | -$231.7M-52.0% | -$152.4M-43.9% | -$105.9M-16.0% | -$91.3M-3.9% | -$87.9M-4.1% | -$84.5M-6.5% | -$79.3M-9.3% | -$72.6M-9.3% | -$66.4M-7.6% | -$61.7M-6.3% | -$58.1M-11.4% | -$52.1M-8.0% | -$48.2M-7.8% | -$44.7M |
CATX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$93.1M | -$82.5M-350.9% | -$18.3M+50.4% | -$36.9M-254.9% | -$10.4M-266.6% | -$2.8M+22.1% | -$3.6M+27.9% | -$5.0M+11.6% | -$5.7M0.0% | -$5.7M-47.1% | -$3.9M-10.3% | -$3.5M-9.1% | -$3.2M-5.6% | -$3.1M-24.9% | -$2.4M-1.2% | -$2.4M |
| Capital Expenditures | $28.1M | $12.7M-76.6% | $54.4M+4975.9% | $1.1M+280.1% | $282K-26.0% | $381K+39.6% | $273K-38.5% | $444K+31.8% | $337K-38.6% | $549K+14.6% | $479K+260.2% | $133K+598.9% | $19K+189.4% | $7K-88.1% | $55K-60.0% | $137K |
| Free Cash Flow | -$121.2M | -$95.2M-31.0% | -$72.7M-91.4% | -$38.0M-255.6% | -$10.7M-232.0% | -$3.2M+17.8% | -$3.9M+28.7% | -$5.5M+9.2% | -$6.0M+3.4% | -$6.3M-43.5% | -$4.4M-19.4% | -$3.7M-12.6% | -$3.2M-6.0% | -$3.1M-22.4% | -$2.5M+2.1% | -$2.6M |
| Investing Cash Flow | -$52.0M | $41.2M+118.8% | -$218.9M-998.3% | $24.4M+184.1% | -$29.0M-6970.2% | -$410K-42.9% | -$287K-171.6% | $401K-78.4% | $1.9M+22.8% | $1.5M-82.7% | $8.8M | N/A | N/A | -$13K+86.6% | -$96K+39.5% | -$158K |
| Financing Cash Flow | $164.7M | $10.3M-96.4% | $289.4M+36764.3% | $785K+2703.6% | $28K-100.0% | $64.7M+6407.4% | $994K-86.5% | $7.4M+1315.4% | $521K+5888.9% | -$9K-123.1% | $39K | N/A | N/A | $3.3M+6.2% | $3.1M+3.1% | $3.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CATX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 100.0%+100.0pp | 0.0%-50.9pp | 50.9%-2.0pp | 52.9%+11.3pp | 41.7%+10.6pp | 31.1%+13.5pp | 17.6%+14.9pp | 2.7%-0.9pp | 3.6%+8.3pp | -4.7%-8.0pp | 3.3%-10.5pp | 13.9%-8.2pp | 22.1% |
| Operating Margin | N/A | N/A | -2855.0% | -140.3% | -34.3%+1.6pp | -35.9%+35.9pp | -71.8% | -113.6% | -132.5% | -106.6% | -94.2% | -108.7% | -89.9%-18.9pp | -71.0%-14.4pp | -56.6% |
| Net Margin | N/A | N/A | -3243.2% | -174.1% | -33.7%+1.9pp | -35.6%+34.7pp | -70.3% | -113.1% | -129.4% | -98.8%-18.9pp | -79.9% | -141.2% | -85.2%-16.4pp | -68.8%-14.5pp | -54.3% |
| Return on Equity | -49.8%-22.5pp | -27.3%+34.6pp | -61.9%-42.2pp | -19.7%-14.7pp | -5.0%+55.2pp | -60.2%+6.8pp | -67.0%+66.2pp | -133.2%-75.1pp | -58.1%-29.4pp | -28.7%-11.0pp | -17.7%+7.2pp | -24.9%+47.0pp | -71.9%-11.9pp | -60.0%-15.9pp | -44.0% |
| Return on Assets | -38.6%-15.4pp | -23.2%+24.3pp | -47.5%-29.0pp | -18.5%-13.7pp | -4.8%+34.8pp | -39.6%+15.0pp | -54.6%+35.3pp | -89.9%-39.7pp | -50.2%-24.2pp | -26.0%-10.0pp | -16.0%+6.5pp | -22.4%+32.2pp | -54.7%-8.2pp | -46.5%-10.4pp | -36.0% |
| Current Ratio | 5.17-7.5x | 12.68+11.6x | 1.07-16.0x | 17.07-20.3x | 37.37+33.9x | 3.50-3.0x | 6.53+3.6x | 2.97-6.3x | 9.30-3.2x | 12.46-2.5x | 14.95-1.7x | 16.65+11.0x | 5.60-0.8x | 6.37+0.9x | 5.45 |
| Debt-to-Equity | 0.010.0x | 0.010.0x | 0.020.0x | 0.060.0x | 0.04-0.5x | 0.52+0.3x | 0.23-0.3x | 0.48+0.3x | 0.16+0.1x | 0.100.0x | 0.110.0x | 0.11-0.2x | 0.310.0x | 0.29+0.1x | 0.22 |
| FCF Margin | N/A | N/A | -2648.9% | -172.9% | -32.0%+8.4pp | -40.4%+34.7pp | -75.1% | -102.1% | -131.5% | -91.5%-12.1pp | -79.3%-2.4pp | -77.0%-9.3pp | -67.7%-18.3pp | -49.4%-0.6pp | -48.8% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Perspective Therapeutics Inc Ranks
Frequently Asked Questions
Is Perspective Therapeutics Inc profitable?
No, Perspective Therapeutics Inc (CATX) reported a net income of -$103.1M in fiscal year 2025.
What is Perspective Therapeutics Inc's EBITDA?
Perspective Therapeutics Inc (CATX) had EBITDA of -$110.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Perspective Therapeutics Inc have?
As of fiscal year 2025, Perspective Therapeutics Inc (CATX) had $30.6M in cash and equivalents against $1.6M in long-term debt.
What is Perspective Therapeutics Inc's return on equity (ROE)?
Perspective Therapeutics Inc (CATX) has a return on equity of -49.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Perspective Therapeutics Inc's free cash flow?
Perspective Therapeutics Inc (CATX) recorded an outflow of $95.2M in free cash flow during fiscal year 2025. This represents a -31.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Perspective Therapeutics Inc's operating cash flow?
Perspective Therapeutics Inc (CATX) recorded an outflow of $82.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Perspective Therapeutics Inc's total assets?
Perspective Therapeutics Inc (CATX) had $267.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Perspective Therapeutics Inc's capital expenditures?
Perspective Therapeutics Inc (CATX) invested $12.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Perspective Therapeutics Inc spend on research and development?
Perspective Therapeutics Inc (CATX) invested $84.2M in research and development during fiscal year 2025.
What is Perspective Therapeutics Inc's current ratio?
Perspective Therapeutics Inc (CATX) had a current ratio of 5.17 as of fiscal year 2025, which is generally considered healthy.
What is Perspective Therapeutics Inc's debt-to-equity ratio?
Perspective Therapeutics Inc (CATX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Perspective Therapeutics Inc's return on assets (ROA)?
Perspective Therapeutics Inc (CATX) had a return on assets of -38.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Perspective Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Perspective Therapeutics Inc (CATX) had $30.6M in cash against an annual operating cash burn of $82.5M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Perspective Therapeutics Inc's Piotroski F-Score?
Perspective Therapeutics Inc (CATX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Perspective Therapeutics Inc's earnings high quality?
Perspective Therapeutics Inc (CATX) reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.